Moderna, Inc. (MRNA)
Levi & Korsinsky Reminds Moderna, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024 - MRNA
NEW YORK, NY / ACCESSWIRE / September 4, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
MRNA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / September 4, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Moderna securities between January 18, 2023, and June 25, 2024, inclusive (the "Class Period").
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 8, 2024 in Moderna Lawsuit – MRNA
NEW YORK, NY / ACCESSWIRE / September 3, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Lost Money on Moderna, Inc.(MRNA)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / September 3, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Notifies Shareholders of Moderna, Inc. (MRNA) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / September 3, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRNA
NEW YORK, NY / ACCESSWIRE / September 3, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
The Schall Law Firm Invites Investor Participation In A Fraud Case Against Moderna Inc.
LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 8, 2024.
Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1
Approval follows recommendation from global public health bodies to develop JN.1 COVID-19 vaccines At present, the JN.1 group of subvariants remain dominant in the UK The updated vaccine will be available for eligible groups as part of the NHS autumn vaccination program, and will also be available to purchase privately in the UK for the first time CAMBRIDGE, MA / ACCESSWIRE / September 3, 2024 / Moderna, Inc. (Nasdaq:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorized its updated COVID-19 vaccine targeting the JN.1 variant of SARS-CoV-2. Following the MHRA decision, doses will be available for eligible groups as part of the NHS autumn vaccination program, which is prioritized for use in people at greatest risk of serious illness from COVID-19.
Levi & Korsinsky Notifies Shareholders of Moderna, Inc.(MRNA) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / September 3, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
MRNA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / September 3, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Moderna securities between January 18, 2023, and June 25, 2024, inclusive (the "Class Period").
MRNA LAWSUIT ALERT: Levi & Korsinsky Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / September 3, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Moderna Inc Is Being Sued For Securities Law Violations And Stockholders Should Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 8, 2024.
